Stocks Health care SGP
NASDAQ · Health careSpyGlass Pharma, Inc. (SGP)
It posted a net loss of $39.9M. In fiscal 2025 capital spending exceeded operating cash flow by $33.5M. At June 30, 2026 it held $223.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about SpyGlass Pharma, Inc.
- Net worth
- SpyGlass Pharma, Inc. has a market value (market cap) of $1.2B at the latest share price, and shareholders' equity of $232.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $32.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- SpyGlass Pharma, Inc.'s next report was expected around October 12, 2026 and is not on file with the SEC yet.
What SpyGlass Pharma, Inc. does
SpyGlass Pharma, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker SGP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$39.9M | -$17.98 | -$33.5M |
| 2025 | n/a | -$29.2M | -$16.31 | -$24M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What SpyGlass Pharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 19, 2026Other event 8-K
- October 1, 2026
- August 6, 2026
- August 6, 2026
- May 14, 2026
- May 14, 2026
- March 26, 2026
- March 26, 2026
- March 9, 2026Other event 8-K
- February 17, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running SpyGlass Pharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| February 9, 2026 | Walker Paul Edward10% owner | Exercised optionsindirect | 1,619,240 | - |
| February 9, 2026 | Walker Paul Edward10% owner | Exercised optionsindirect | 1,370,168 | - |
| February 9, 2026 | Walker Paul Edward10% owner | Exercised optionsindirect | 1,370,168 | - |
| February 9, 2026 | Walker Paul Edward10% owner | Exercised optionsindirect | 737,962 | - |
| February 9, 2026 | Walker Paul Edward10% owner | Boughtindirect | 937,500 | $15M |
| February 9, 2026 | Walker Paul Edward10% owner | Exercised optionsindirect | 954,990 | - |
| February 9, 2026 | Walker Paul Edward10% owner | Exercised optionsindirect | 402,273 | - |
| February 9, 2026 | Chang Carmen10% owner | Exercised optionsindirect | 1,619,240 | - |
Who owns SGP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RA Capital Management, L.P.13D, may seek influence with 4 related filers | 24.1% | February 17, 2026 |
| Ali Behbahani13D, may seek influence with 14 related filers | 22.2% | February 13, 2026 |
| Kirk Nielsen13D, may seek influence with 3 related filers | 9.9% | February 10, 2026 |
| Sands Frank M.13G, passive with 3 related filers | 7.8% | February 13, 2026 |
| Gilde Healthcare Holding B.V.13D, may seek influence with 4 related filers | 6.57% | February 13, 2026 |
| Srinivas Akkaraju13G, passive with 4 related filers | 6.3% | February 17, 2026 |
Largest institutional holders
Insiders
15 insiders reported holding 38,746,261 shares in total, about $1.32B at the last price.
| Holder | Shares |
|---|---|
| Yang Rick10% owner | 6,035,0386,035,038 held indirectly |
| Mathers Edward T10% owner | 6,035,0386,035,038 held indirectly |
| New Enterprise Associates 17, L.P.10% owner | 6,035,038 |
| Vensana Capital I GP, LLC10% owner | 3,310,6193,310,619 held indirectly |
| Nielsen Kirk G.Director | 3,310,6193,310,619 held indirectly |
| Pardo Geoffrey BDirector | 2,187,5132,187,513 held indirectly |
| Ra Capital Management, L.P.Director, 10% owner | 2,054,6782,054,678 held indirectly |
| Sandell Scott D10% owner | 1,357,2631,357,263 held indirectly |
| Baskett Forest10% owner | 1,357,2631,357,263 held indirectly |
| Walker Paul Edward10% owner | 1,357,2631,357,263 held indirectly |
Questions about SGP
What does SpyGlass Pharma, Inc. do?
SpyGlass Pharma, Inc. is a company in the Health care sector, listed on NASDAQ as SGP. Its shares trade on NASDAQ under the ticker SGP.
What is SpyGlass Pharma, Inc.'s net worth?
SpyGlass Pharma, Inc. has a market value (market cap) of $1.2B at the latest share price, and shareholders' equity of $232.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is SpyGlass Pharma, Inc. profitable?
No. In fiscal 2025 it reported a net loss of $39.9M.
When did SpyGlass Pharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from October 19, 2026.
When is SpyGlass Pharma, Inc.'s next earnings report?
SpyGlass Pharma, Inc.'s next report was expected around October 12, 2026 and is not on file with the SEC yet.
Similar companies
Compare SGP with
Follow SGP
Get an email when SpyGlass Pharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values SpyGlass Pharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.